Literature DB >> 19103766

An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity.

Mark Baer1, Teiji Sawa, Peter Flynn, Kenneth Luehrsen, David Martinez, Jeanine P Wiener-Kronish, Geoffrey Yarranton, Christopher Bebbington.   

Abstract

Pseudomonas aeruginosa is an opportunistic pathogen that can cause acute lung injury and mortality through the delivery of exotoxins by the type III secretion system (TTSS). PcrV is an important structural protein of the TTSS. An engineered human antibody Fab fragment that binds to the P. aeruginosa PcrV protein with high affinity has been identified and has potent in vitro neutralization activity against the TTSS. The instillation of a single dose of Fab into the lungs of mice provided protection against lethal pulmonary challenge of P. aeruginosa and led to a substantial reduction of viable bacterial counts in the lungs. These results demonstrate that blocking of the TTSS by a Fab lacking antibody Fc-mediated effector functions can be sufficient for the effective clearance of pulmonary P. aeruginosa infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19103766      PMCID: PMC2643635          DOI: 10.1128/IAI.00815-08

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.609


  34 in total

1.  Characterization of a humanized monoclonal antibody recognizing clumping factor A expressed by Staphylococcus aureus.

Authors:  Paul J Domanski; Pratiksha R Patel; Arnold S Bayer; Li Zhang; Andrea E Hall; Peter J Syribeys; Elena L Gorovits; Dawn Bryant; John H Vernachio; Jeff T Hutchins; Joseph M Patti
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

2.  Identification of type III secreted products of the Pseudomonas aeruginosa exoenzyme S regulon.

Authors:  T L Yahr; L M Mende-Mueller; M B Friese; D W Frank
Journal:  J Bacteriol       Date:  1997-11       Impact factor: 3.490

Review 3.  Histology and microbiology of ventilator-associated pneumonias.

Authors:  J J Rouby
Journal:  Semin Respir Infect       Date:  1996-03

4.  Therapeutic administration of anti-PcrV F(ab')(2) in sepsis associated with Pseudomonas aeruginosa.

Authors:  N Shime; T Sawa; J Fujimoto; K Faure; L R Allmond; T Karaca; B L Swanson; E G Spack; J P Wiener-Kronish
Journal:  J Immunol       Date:  2001-11-15       Impact factor: 5.422

5.  Pore-forming activity of type III system-secreted proteins leads to oncosis of Pseudomonas aeruginosa-infected macrophages.

Authors:  D Dacheux; J Goure; J Chabert; Y Usson; I Attree
Journal:  Mol Microbiol       Date:  2001-04       Impact factor: 3.501

6.  Passive anti-PcrV treatment protects burned mice against Pseudomonas aeruginosa challenge.

Authors:  Alice N Neely; Ian A Holder; Jeanine P Wiener-Kronish; Teiji Sawa
Journal:  Burns       Date:  2005-03       Impact factor: 2.744

7.  Pseudomonas aeruginosa cystic fibrosis isolates induce rapid, type III secretion-dependent, but ExoU-independent, oncosis of macrophages and polymorphonuclear neutrophils.

Authors:  D Dacheux; B Toussaint; M Richard; G Brochier; J Croize; I Attree
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

8.  Defects in type III secretion correlate with internalization of Pseudomonas aeruginosa by epithelial cells.

Authors:  A R Hauser; S Fleiszig; P J Kang; K Mostov; J N Engel
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

Review 9.  PEGylated antibodies and antibody fragments for improved therapy: a review.

Authors:  Andrew P Chapman
Journal:  Adv Drug Deliv Rev       Date:  2002-06-17       Impact factor: 15.470

10.  The changing epidemiology of cystic fibrosis.

Authors:  S C FitzSimmons
Journal:  J Pediatr       Date:  1993-01       Impact factor: 4.406

View more
  41 in total

1.  A Structure-Function-Inhibition Analysis of the Pseudomonas aeruginosa Type III Secretion Needle Protein PscF.

Authors:  Donald T Moir; Nicholas O Bowlin; Bryan J Berube; Jaden Yabut; Debra M Mills; Giang T Nguyen; Zachary D Aron; John D Williams; Joan Mecsas; Alan R Hauser; Terry L Bowlin
Journal:  J Bacteriol       Date:  2020-08-25       Impact factor: 3.490

Review 2.  Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa.

Authors:  Souha S Kanj; Zeina A Kanafani
Journal:  Mayo Clin Proc       Date:  2011-03       Impact factor: 7.616

3.  The best defense is a good (Protease) offense: How Pseudomonas aeruginosa evades mucosal immunity in the lung.

Authors:  Lisa A Miller
Journal:  Virulence       Date:  2017-01-19       Impact factor: 5.882

4.  Computational design of a CNT carrier for a high affinity bispecific anti-HER2 antibody based on trastuzumab and pertuzumab Fabs.

Authors:  Karim Salazar-Salinas; Carlos Kubli-Garfias; Jorge M Seminario
Journal:  J Mol Model       Date:  2012-11-10       Impact factor: 1.810

Review 5.  Recent developments for Pseudomonas vaccines.

Authors:  Anurag Sharma; Anja Krause; Stefan Worgall
Journal:  Hum Vaccin       Date:  2011-10-01

6.  A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models.

Authors:  Paul Warrener; Reena Varkey; Jessica C Bonnell; Antonio DiGiandomenico; Maria Camara; Kimberly Cook; Li Peng; Jingying Zha; Partha Chowdury; Bret Sellman; C Kendall Stover
Journal:  Antimicrob Agents Chemother       Date:  2014-05-19       Impact factor: 5.191

7.  Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa.

Authors:  Teiji Sawa; Emi Ito; Vinh Huu Nguyen; Matthew Haight
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

8.  Mutations in the Pseudomonas aeruginosa needle protein gene pscF confer resistance to phenoxyacetamide inhibitors of the type III secretion system.

Authors:  Nicholas O Bowlin; John D Williams; Claire A Knoten; Matthew C Torhan; Tommy F Tashjian; Bing Li; Daniel Aiello; Joan Mecsas; Alan R Hauser; Norton P Peet; Terry L Bowlin; Donald T Moir
Journal:  Antimicrob Agents Chemother       Date:  2014-01-27       Impact factor: 5.191

Review 9.  Vaccines for Pseudomonas aeruginosa: a long and winding road.

Authors:  Gregory P Priebe; Joanna B Goldberg
Journal:  Expert Rev Vaccines       Date:  2014-02-27       Impact factor: 5.217

10.  The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa.

Authors:  Mao Kinoshita; Hideya Kato; Hiroaki Yasumoto; Masaru Shimizu; Saeko Hamaoka; Yoshifumi Naito; Koichi Akiyama; Kiyoshi Moriyama; Teiji Sawa
Journal:  Hum Vaccin Immunother       Date:  2016-07-25       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.